Loading

David Ambinder, MD

David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.

Articles by David Ambinder, MD

David Ambinder, MD

Journal | August 24, 2022

Studies on the use of cytoreductive nephrectomy in mRCC are reviewed, including its role among TKIs and immunotherapy.

David Ambinder, MD

Journal | August 24, 2022

Dr. Stacy Loeb is interviewed on the use of active surveillance for prostate cancer, its history, and new insights.

David Ambinder, MD

Journal | August 24, 2022

The utility of using AI to help determine scoring and surgical options for kidney cancer is examined against human scoring.

David Ambinder, MD

Journal | July 27, 2022

The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.

David Ambinder, MD

Journal | July 27, 2022

Benjamin Davies, MD, gives his insight on how to reduce the use of opiates for patients after urologic surgery.

David Ambinder, MD

Journal | July 27, 2022

Active surveillance and enzalutamide monotherapy for localized prostate cancer is compared with active surveillance alone.

David Ambinder, MD

Journal | June 24, 2022

Reviewing a JAMA report on the effect of robot-assisted radical cystectomy in bladder cancer, along with the RAZOR trial.

David Ambinder, MD

Journal | June 24, 2022

An analysis of the HERO trial discussing the safety of relugolix, including major adverse cardiovascular events.

David Ambinder, MD

Journal | June 24, 2022

Dr. Ambinder discusses the use of focal therapy for prostate cancer and if it should be considered standard of care.

David Ambinder, MD

Journal | May 27, 2022

Phillip Pierorazio, MD, shares his motivation and gives insight into what it means to practice with mindfulness in surgery.